Related Experiment Video

Updated: Jun 8, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

[Current anti-influenza virus chemotherapy]

Daisuke Yoshioka1, Issei Tokimatsu, Hiroshi Ishii

  • 1Internal Medicine II, Oita University, Faculty of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 18, 2010
PubMed

Insights

Pandemic H1N1 influenza requires careful drug selection. Amantadine is ineffective, while oseltamivir resistance is a growing concern, necessitating monitoring of antiviral efficacy.

Area of Science:

  • Virology
  • Epidemiology
  • Infectious Diseases

Background:

  • The global influenza landscape is evolving, marked by the 2009 pandemic (H1N1).
  • Effective influenza control is crucial worldwide.
  • Antiviral drug resistance presents a significant challenge to public health.

Purpose of the Study:

  • To review the current status of antiviral drugs for influenza in Japan.
  • To highlight the emergence of drug-resistant influenza strains.
  • To inform clinical practice regarding appropriate antiviral selection.

Main Methods:

  • Literature review of antiviral drug efficacy and resistance patterns.
  • Analysis of available anti-influenza medications in Japan.
  • Discussion of clinical recommendations for pandemic (H1N1) 2009 and seasonal influenza.

Main Results:

  • Amantadine is ineffective against pandemic (H1N1) 2009 due to widespread resistance.
  • Oseltamivir is widely used but resistance is emerging.
  • Zanamivir exhibits low resistance rates; peramivir offers an intravenous option for severe cases.

Conclusions:

  • Antiviral resistance necessitates ongoing surveillance and strategic drug use.
  • Oseltamivir resistance is a key concern for pandemic (H1N1) 2009 management.
  • Peramivir provides a valuable therapeutic option for severe influenza infections.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...